Caris publishes study validating AI approach to pancreatic cancer treatment selection
Caris Life Sciences said a study in npj Precision Oncology validated Caris AI Insights for first-line pancreatic cancer treatment selection, including guidance between FOLFIRINOX and gemcitabine plus nab-paclitaxel.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.